exendin based glp 1 Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy Achieve your results faster with highly validated GLP-1-based therapies for type 2

10.3233/JAD-140198 J

Of 41,792 patients who discontinued and had post-discontinuation weight data, 1-year reinitiation was lower in patients without T2D (36.3% restarted within a year) compared to those with T2D (47.3% restarted within a year)

Data availability The data underlying the results presented in this study are available from the corresponding author upon submission of a legitimate request

It can be found that compared with the Model group, the Low group and High group secreted more insulin after berberine treatment (Figure 1I), and calculated homeostatic model assessment of insulin resistance (HOMA-IR) index according to the following formula: HOMA-IR = FBG (mM) Fasting insulin (mU/L)/22.5 (Figure 1J)

What side effects can these peptides cause